Halozyme Therapeutics (HALO) to Release Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) will release its earnings data after the market closes on Tuesday, May 10th. Analysts expect Halozyme Therapeutics to post earnings of $0.44 per share for the quarter. Halozyme Therapeutics has set its FY 2022 guidance at $2.050-$2.200 EPS and its FY22 guidance at $2.05-2.20 EPS.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings results on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.04. Halozyme Therapeutics had a return on equity of 164.68% and a net margin of 90.84%. The company had revenue of $102.00 million during the quarter, compared to analysts’ expectations of $97.10 million. On average, analysts expect Halozyme Therapeutics to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Halozyme Therapeutics stock traded up $0.06 during midday trading on Wednesday, hitting $41.00. 590 shares of the company’s stock were exchanged, compared to its average volume of 866,766. The company has a debt-to-equity ratio of 4.00, a quick ratio of 7.45 and a current ratio of 7.91. Halozyme Therapeutics has a 52-week low of $31.36 and a 52-week high of $48.97. The stock has a 50-day moving average price of $39.15 and a two-hundred day moving average price of $37.22. The company has a market cap of $5.65 billion, a P/E ratio of 14.91 and a beta of 1.24.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in shares of Halozyme Therapeutics by 0.7% during the fourth quarter. BlackRock Inc. now owns 19,439,863 shares of the biopharmaceutical company’s stock worth $781,676,000 after purchasing an additional 144,483 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Halozyme Therapeutics by 43.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,076,833 shares of the biopharmaceutical company’s stock worth $43,300,000 after buying an additional 323,585 shares during the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Halozyme Therapeutics by 4.5% in the 4th quarter. Allianz Asset Management GmbH now owns 586,274 shares of the biopharmaceutical company’s stock valued at $23,575,000 after purchasing an additional 25,161 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Halozyme Therapeutics by 18.6% during the 4th quarter. Sei Investments Co. now owns 443,653 shares of the biopharmaceutical company’s stock valued at $17,856,000 after buying an additional 69,515 shares during the period. Finally, Parametric Portfolio Associates LLC increased its holdings in Halozyme Therapeutics by 5.1% during the 4th quarter. Parametric Portfolio Associates LLC now owns 293,558 shares of the biopharmaceutical company’s stock worth $11,804,000 after purchasing an additional 14,233 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

HALO has been the topic of several analyst reports. Zacks Investment Research raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating and set a $37.00 price target on the stock in a report on Monday, March 14th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Piper Sandler cut their price objective on shares of Halozyme Therapeutics from $43.00 to $42.00 in a report on Wednesday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $47.83.

About Halozyme Therapeutics (Get Rating)

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles